Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v7-EN | Version v1-EN | |
---|---|---|
Language | English | English |
Date Updated | 2021-10-22 | 2021-10-01 |
Drug Identification Number | 02139545 | 02139545 |
Brand name | POTASSIUM PHOSPHATES INJECTION, USP | POTASSIUM PHOSPHATES INJECTION, USP |
Common or Proper name | Potassium Phosphates Injection, USP PBP Vial 3 mmol / mL 50 mL | Potassium Phosphates Injection, USP PBP Vial 3 mmol / mL 50 mL |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
Strength(s) | 236MG 224MG | 236MG 224MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 50 mL | 50 mL |
ATC code | B05XA | B05XA |
ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-10-01 | 2021-10-01 |
Actual start date | 2021-10-01 | 2021-10-01 |
Estimated end date | 2021-10-12 | 2021-10-12 |
Actual end date | 2021-10-21 | |
Shortage status | Resolved | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | Please be advise that there will be a short supply gap starting October 1, 2021 as we transition from the old code to the new code for Potassium Phosphates Injection, USP 3 mmol / mL 50mL vial. The 15mL is available for substitution. | |
Health Canada comments |